Latest Breaking News On - Dana cormack - Page 5 : comparemela.com

REGENXBIO Presents Positive One Year Data from Phase II ALTITUDE® Trial of ABBV-RGX-314 for Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery

REGENXBIO Presents Positive One Year Data from Phase II ALTITUDE® Trial of ABBV-RGX-314 for Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSan franciscoSteve pakolaDana cormackChris brinzeyMark barakatPeter kaiserAmerican academy of ophthalmologyTechnology platformCleveland clinic lerner college of medicineSecurities exchangeExchange commissionCorporate communicationsTechnology platform licenseesOphthalmology researchClearside biomedical inc

REGENXBIO Presents Positive One Year Data from Phase II ALTITUDE® Trial of ABBV-RGX-314 for Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery

ABBV-RGX-314 continues to be well tolerated in 50 patients from dose levels 1 and 2 (Cohorts 1-3) with no drug-related serious adverse events Dose level 2.

United statesSan franciscoSteve pakolaPeter kaiserChris brinzeyDana cormackMark barakatAmerican academy of ophthalmologyTechnology platformExchange commissionCole eye instituteCorporate communicationsTechnology platform licenseesClearside biomedical incOphthalmology researchSecurities exchange

REGENXBIO to Host Conference Call on November 8 to Discuss Third Quarter 2023 Financial Results and Recent Operational Highlights

ROCKVILLE, Md., Nov. 1, 2023 /PRNewswire/ REGENXBIO Inc. today announced that it will host a conference call on Wednesday, November 8, 2023, at 4:30 p.m. EST to discuss its financial results for.

Chris brinzeyDana cormackTechnology platform licenseesCorporate communicationsTechnology platformPlatform licensees

REGENXBIO to Participate in the Jefferies CNS/Neuro Summit

ROCKVILLE, Md., Oct. 5, 2023 /PRNewswire/ REGENXBIO Inc. today announced it will participate in the Jefferies CNS/Neuro Summit on Thursday, October 12, 2023. Jefferies CNS/Neuro.

New yorkUnited statesChris brinzeyDana cormackCorporate communicationsTechnology platform licenseesTechnology platformNeuro summitPlatform licensees

REGENXBIO Presents Interim Clinical Data from Phase I/II AFFINITY DUCHENNE™ Trial of RGX-202 at 28th Annual International Congress of the World Muscle Society

RGX-202, a potential one-time AAV Therapeutic for the treatment of Duchenne that includes an optimized transgene for a novel microdystrophin, continues to be.

United statesDana cormackAravindhan veerapandiyanOlivier danosChris brinzeyClinical program updatesTechnology platformInternational congressCorporate communicationsManufacturing innovation centerWorld muscle societyExchange commissionTechnology platform licenseesSecurities exchangeBiologics license applicationDuchenne muscular dystrophy